Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01WKE
|
|||
| Former ID |
DIB012772
|
|||
| Drug Name |
Semapimod
|
|||
| Synonyms |
CPSI-2364; Semapimod (oral); Semapimod (oral), Cytokine PharmaSciences
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Phase 2 | [1] | |
| Inflammatory bowel disease [ICD-11: DD72; ICD-10: K50-K52] | Phase 2 | [1] | ||
| Company |
Cytokine PharmaSciences Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C34H52N18O2
|
|||
| Canonical SMILES |
CC(=NN=C(N)N)C1=CC(=CC(=C1)NC(=O)CCCCCCCCC(=O)NC2=CC(=CC(=C2)C(=NN=C(N)N)C)C(=NN=C(N)N)C)C(=NN=C(N)N)C
|
|||
| InChI |
1S/C34H52N18O2/c1-19(45-49-31(35)36)23-13-24(20(2)46-50-32(37)38)16-27(15-23)43-29(53)11-9-7-5-6-8-10-12-30(54)44-28-17-25(21(3)47-51-33(39)40)14-26(18-28)22(4)48-52-34(41)42/h13-18H,5-12H2,1-4H3,(H,43,53)(H,44,54)(H4,35,36,49)(H4,37,38,50)(H4,39,40,51)(H4,41,42,52)/b45-19+,46-20+,47-21+,48-22+
|
|||
| InChIKey |
PWDYHMBTPGXCSN-VCBMUGGBSA-N
|
|||
| CAS Number |
CAS 352513-83-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proto-oncogene c-RAF (c-RAF) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00038766) CNI-1493 for Treatment of Moderate to Severe Crohn's Disease. U.S. National Institutes of Health. | |||
| REF 2 | Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease. J Immunol. 2005 Aug 15;175(4):2293-300. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.